Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06885905

Acronym

CAPSULE

Enrollment

100

Registered

2025-03-20

Start date

2024-11-27

Completion date

2026-04-23

Last updated

2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pulmonary Aspergillosis

Keywords

CPA

Brief summary

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. All patients \>/= 18 years old and able to provide informed consent 2. Patients with a diagnosis of chronic pulmonary aspergillosis 3. To speak and understand English 4. Able to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.	30 months	To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)

Secondary

Measure	Time frame	Description
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.	30 months	Testing the usability of a newly developed CPA-HAQ measure.

Countries

United Kingdom

Contacts

Primary ContactDareen Marghlani, MSc

dsm20@ic.ac.ukdsm20@ic.ac.uk

Backup ContactAnand Shah, PhD

s.anand@imperial.ac.uk

Outcome results